An Open-label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Induction Treatment with Melphalan/HDS Followed by Consolidation Treatment with Eribulin or Vinorelbine or Capecitabine Versus Eribulin or Vinorelbine or Capecitabine Alone in Patients with Metastatic Breast Cancer with Liver Dominant Disease

The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy followed by approved cancer treatment to treat patients with breast cancer that has spread to the liver is safe and tolerable. The clinical trial will also learn if the liver-directed therapy with high dose chemotherapy works on the disease in the liver. Investigators will compare the use of the liver-directed therapy with high dose chemotherapy followed by approved cancer treatment or approved cancer treatment alone.
Participants will:
* Undergo up to two cycles of liver-directed therapy with high dose chemotherapy procedures followed by approved cancer treatment or take approved cancer treatment alone
* Visit clinic at least every two weeks for checkups and tests
* Complete scans approximately every 8 weeks

Start Date01 Sep 2025

Sponsor / Collaborator

Delcath Systems, Inc.

NCT06590558

/ RecruitingPhase 1IIT

Phase I/Ib Study of Eribulin in Combination With ASTX660 (Tolinapant) in Metastatic Triple Negative Breast Cancer (TNBC)

This phase I/Ib trial tests the safety, side effects, best dose, and effectiveness of ASTX660 (tolinapant) in combination with eribulin mesylate (eribulin) in treating patients with triple negative breast cancer that cannot be removed by surgery (unresectable) or that has spread to nearby tissues or lymph nodes (locally advanced) or to other places in the body (metastatic). Tolinapant may stop the growth of tumor cells by blocking proteins, such as XIAP and cIAP1, needed for tumor cell survival. Chemotherapy drugs, such as eribulin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving tolinapant in combination with eribulin may be safe, tolerable, and/or effective in treating patients with unresectable, locally advanced, or metastatic triple negative breast cancer.

Start Date04 Aug 2025

Sponsor / Collaborator

National Cancer Institute

NCT06889688

/ Not yet recruitingPhase 3IIT

A Multicenter, Phase III, Randomized Controlled Trial Comparing Camrelizumab Plus Apatinib and Eribulin Versus Physician's Choice Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

This study evaluates the efficacy and safety of camrelizumab, apatinib, and eribulin versus physician's choice chemotherapy in advanced TNBC.Primary Objectives: Assess improvements in progression-free survival (PFS) and overall survival (OS).Secondary Objectives: Compare objective response rate (ORR), disease control rate (DCR), clinical benefit rate (CBR), duration of response (DoR), time to response (TTR), two-year OS rate, biomarker analysis, and quality of life (QoL).Safety: Assess and compare adverse event incidence and severity.

Start Date01 Apr 2025

Sponsor / Collaborator

Sun Yat-Sen Memorial Hospital

100 Clinical Results associated with Eribulin mesylate

100 Translational Medicine associated with Eribulin mesylate

100 Patents (Medical) associated with Eribulin mesylate

1,476

Literatures (Medical) associated with Eribulin mesylate

16 Feb 2025·CHEMBIOCHEM

A Novel Concept for Cleavable Linkers Applicable to Conjugation Chemistry – Design, Synthesis and Characterization

Article

Author: Amy Siu, Y. ; Fang, Hui ; McGonigle, Sharon ; Li, Danyang ; Majumder, Utpal ; Custar, Daniel ; Postema, Maarten ; Lai, Weidong ; Bresciano, Karen ; Hart, Andrew ; Cheng, Xin ; Zhu, Xiaojie ; Albone, Earl

Abstract:

Linkers with disulfide bonds are the only cleavable linkers that utilize physiological thiol gradients as a trigger to initiate the intracellular drug release cascade. Herein, we present a novel concept exploiting the thiol gradient phenomena to design a new class of cleavable linker with no disulfide bond. To support the concept, an electron‐deficient sulfonamide‐based cleavable linker amenable to conjugation of drug molecules with targeting agents, was developed. Modulating the electron‐withdrawing nature of the aryl sulfonamide was critical to the balance between the stability and drug release. Favorable stability and payload release in human serum under physiologically relevant thiol concentrations was demonstrated with two potent cytotoxics. Intracellular payload release was further validated in cell‐based assay in context of antibody‐drug conjugate generated from monoclonal antibody and sulfonamide containing linker. To support the proposed release mechanism, possible downstream by‐products formed from the drug‐linker adduct were characterized.

04 Feb 2025·MOLECULAR CANCER THERAPEUTICS

Potential Mechanisms of Interstitial Lung Disease Induced by Antibody–Drug Conjugates Based on Quantitative Analysis of Drug Distribution

Article

Author: Koganemaru, Shigehiro ; Doi, Toshihiko ; Yasunaga, Masahiro ; Shinohara, Hiroko ; Uenaka, Toshimitsu ; Kuboki, Yasutoshi ; Morizono, Chihiro ; Fuchigami, Hirobumi ; Furuuchi, Keiji

Abstract:

Antibody–drug conjugates (ADC) are a rapidly advancing category of therapeutic agents with notable anticancer efficacy. However, the emergence of interstitial lung disease as a severe ADC-associated adverse event highlights the need to better understand the underlying mechanisms. In this study, xenograft model mice with tumors expressing different levels of the trophoblast antigen 2 (TROP2) were generated by subcutaneously transplanting the various TROP2-expressing cancer lines. The mice received different doses of TROP2–eribulin, a novel TROP2-targeting ADC, composed of an anti-TROP2 antibody and the eribulin payload, joined by a cleavable linker. The concentration and distribution of TROP2–eribulin, as well as the pharmacokinetics of eribulin release, were assessed in tumor and lung tissues. Analysis of tumor tissue showed that the concentration of released eribulin was approximately 10-fold higher in NCI-H2110 (high TROP2 expression) than in A549 (low TROP2 expression), whereas analysis of lung tissue showed that TROP2–eribulin was distributed in lung tissue in a dose-dependent manner, regardless of TROP2 expression, with significantly more eribulin released in the high-dose group than in the other dose groups (P < 0.05). Immunofluorescence assay analysis showed that TROP2–eribulin localized to alveolar macrophages. In the analysis using human leukemia monocytic cell, the concentration of eribulin released from TROP2–eribulin was significantly reduced by the use of an Fc receptor inhibitor (P < 0.05). These results revealed that Fcγ receptor–mediated uptake by alveolar macrophages releases the cytotoxic payload into lung tissue, helping to clarify the pathogenesis of ADC-induced interstitial lung disease.

01 Feb 2025·Geriatrics & Gerontology International

Efficacy of eribulin monotherapy for bone marrow carcinomatosis of breast cancer in a patient with Werner syndrome

Article

Author: Uhara, Hisashi ; Kutomi, Goro ; Fujimi, Akihito ; Nishisato, Takuji ; Murase, Kazuyuki ; Gotoh, Yoshiro ; Takada, Kohichi ; Nagamachi, Yasuhiro ; Matsuno, Teppei ; Yamauchi, Naofumi ; Kato, Junji ; Hayasaka, Naotaka ; Ihara, Kohji ; Koike, Kazuhiko ; Hasebe, Riku ; Hida, Tokimasa ; Onoyama, Naoki

Various complications and potential risks of serious adverse events lessens the intensity of chemotherapy in patients with Werner syndrome. Bone marrow carcinomatosis of breast cancer was developed in a patient with Werner syndrome. Eribulin proved well tolerated and effective in improving severe thrombocytopenia, leading to platelet transfusion-free status.

131

News (Medical) associated with Eribulin mesylate

21 Mar 2025

·www.fiercebiotech.com

Eisai\'s abandoned Enhertu challenger set to live on at BlissBio

Angle, a liquid biopsy company, said the full phase 2 study of BB-1701 is ongoing and the drug efficacy results are unknown. \n BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. Weeks after Eisai quietly made its choice, its liquid biopsy partner has revealed Bliss Biopharmaceutical plans to progress the program independently.Eisai agreed to pay BlissBio up to $2 billion to secure an option on BB-1701 in 2023. By then, AstraZeneca and cancer drug partner Daiichi Sankyo had already validated the blockbuster potential of HER2-directed ADCs with Enhertu. But Eisai identified BB-1701 as a potential best-in-class molecule, citing its eribulin-based payload-linker technology as a differentiator that could enable the ADC to carve out a niche in the HER2 space.The partners went on to report responses in solid tumors, including in breast cancer patients who had previously received another anti-HER2 ADC. Yet, last month, Eisai revealed (PDF) it had decided not to exercise its BB-1701 option. The Japanese drugmaker recorded an impairment loss tied to the decision. Eisai’s decision had implications for Angle, a liquid biopsy company that provided circulating tumor cell analysis to a phase 2 trial of BB-1701. Friday, Angle said the trial showed its assay can measure changes in HER2 status over time, potentially giving the test an advantage over tissue-based assessments. Angle said the full phase 2 study of BB-1701 is ongoing and the drug efficacy results are unknown. Eisai has tapped out before seeing the results, but Angle said BlissBio has confirmed its intention to progress the ADC independently. The diagnostic company is now seeking to work with BlissBio on the next stage of BB-1701 development. Eisai will continue to work with BlissBio as a licensor for the eribulin payload.The changes leave China’s BlissBio without a global partner for BB-1701. BlissBio faces competition in its home market from a clutch of local companies such as Duality Biologics, GeneQuantum Healthcare and Jiangsu HengRui Medicine. BioNTech licensed ex-China rights to DualityBio’s candidate in 2023. Johnson & Johnson picked up a HER2-directed ADC in its $2 billion takeover of Ambrx last year.

$Eisai\'s abandoned Enhertu challenger set to live on at BlissBio$

ADCAcquisitionPhase 2

10 Feb 2025

·www.prnewswire.com

BioRay's ROR1-Targeting Dual-Epitope ADC Drug BR111 Receives Formal Clinical Trial Approval from NMPA

SHANGHAI, Feb. 10, 2025 /PRNewswire/ -- On December 19, 2024, BioRay Pharmaceutical Co., Ltd. ("BioRay") announced that the National Medical Products Administration (NMPA) has accepted the clinical trial application for its self-developed Class 1 innovative therapeutic biological product, BR111 for injection. BR111 is an antibody-drug conjugate (ADC) targeting dual epitopes of ROR1, intended for the treatment of ROR1-positive hematological malignancies and solid tumors. ROR1 is a transmembrane receptor tyrosine kinase protein that is either not expressed or expressed at low levels in normal tissues, but is highly expressed in various hematological malignancies and solid tumors, such as lymphoma, breast cancer, ovarian cancer, and lung cancer. ROR1 is involved in the non-canonical Wnt signaling pathway mediated by Wnt5a, regulating the growth and invasion of tumor cells. It is closely associated with tumorigenesis and drug resistance, making it a potential target for oncology drug development. To date, no ROR1-targeting drugs have been marketed. BR111 utilizes BioRay's next-generation CysX™ irreversible site-specific conjugation technology platform to conjugate an antibody targeting dual epitopes of ROR1 with the small-molecule toxin eribulin. It is the world's first anti-ROR1 Bi-paratopic ADC to enter clinical trials. BR111 can recognize two non-overlapping epitopes of ROR1 on the surface of tumor cells, and dual-epitope recognition brings stronger affinity and endocytosis. Once endocytosed into ROR1-positive tumor cells, BR111 releases the small-molecule toxin in the lysosome, effectively killing tumor cells. Developed using the CysX™ platform, BR111 has higher homogeneity and circulating stability, significantly reducing toxin release in circulation, which enhances safety and optimizes the therapeutic window. In preclinical studies, BR111 demonstrated superior in vivo anti-tumor efficacy compared to its clinical counterparts in multiple animal models and exhibited better safety. Additionally, BR111 can induce a bystander effect and activate immune response in the tumor microenvironment, showing potential for combination therapy with various drugs, including targeted therapies and immunotherapies. The acceptance of this project application is a testament to BioRay's R&D capabilities and a validation of the CysX™ platform technology. Moving forward, BioRay will continue to focus on clinical needs, drive innovative research, and advance biopharmaceutical technology, with the goal of delivering more effective and safer treatment options to patients through innovative drugs. SOURCE BioRay Pharmaceutical Co., Ltd WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

ADCImmunotherapyIND

31 Jan 2025

·www.businesswire.com

Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

TOKYO & MUNICH--( BUSINESS WIRE )--Datopotamab deruxtecan (Dato-DXd) has been recommended for approval in the European Union (EU) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine therapy and at least one line of chemotherapy in the advanced setting. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE:45680) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast01 phase 3 trial published in the Journal of Clinical Oncology . The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast01, datopotamab deruxtecan significantly reduced the risk of disease progression or death by 37% compared to investigator’s choice of chemotherapy (hazard ratio [HR]=0.63; 95% confidence interval [CI]: 0.52-0.76; p<0.0001) in patients with HR positive, HER2 negative metastatic breast cancer as assessed by blinded independent central review (BICR). Median progression-free survival (PFS) was 6.9 months in patients treated with datopotamab deruxtecan versus 4.9 months with chemotherapy. A confirmed objective response rate (ORR) of 36% was observed in the datopotamab deruxtecan arm compared to an ORR of 23% observed in the chemotherapy arm. Two (0.5%) complete responses (CR) and 131 (36%) partial responses (PR) were observed in the datopotamab deruxtecan arm compared to zero CR and 84 PR (23%) in the chemotherapy arm. The median duration of response (DoR) was 6.7 months (95% CI: 5.6-9.8) in the datopotamab deruxtecan arm compared to 5.7 (95% CI: 4.9-6.8) in the chemotherapy arm. Datopotamab deruxtecan demonstrated a favorable safety profile over chemotherapy with no new safety concerns identified. Grade 3 or higher treatment-related adverse events (TRAEs) occurred in 21% and 45% of patients in the datopotamab deruxtecan and chemotherapy arms, respectively. The most common grade 3 or higher TRAEs were neutropenia (1% vs. 31%), stomatitis (6% vs. 3%), fatigue (2% vs. 2%) and anemia (1% vs. 2%). In the datopotamab deruxtecan arm, the all-grade interstitial lung disease (ILD) rate was low (3%) and the majority of events were low grade. There was one grade 5 ILD event adjudicated as drug related by an independent committee. The primary cause of death in this case was attributed to disease progression by the treating investigator. “ Disease progression after endocrine and initial chemotherapy is common in patients with metastatic HR positive, HER2 negative breast cancer,” said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. “ This positive recommendation by the CHMP for datopotamab deruxtecan, which follows recent approvals in the U.S. and Japan, underscores the potential of this TROP2 directed antibody drug conjugate to offer a new treatment option to patients in the EU with this type of breast cancer.” “ Only one in three patients live more than five years after a metastatic HR positive, HER2 negative breast cancer diagnosis, underscoring the urgent need for additional effective therapies,” said Susan Galbraith, MBBChir, PhD, Executive Vice President, Oncology Hematology R&D, AstraZeneca. “ Today’s recommendation for datopotamab deruxtecan brings us closer to offering these patients in the EU a new and needed alternative to conventional chemotherapy.” Datopotamab deruxtecan is approved in Japan and the U.S. for the treatment of patients with unresectable or metastatic HR positive, HER2 negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. Additional regulatory submissions for datopotamab deruxtecan in breast cancer are under review in China and other regions. About TROPION-Breast01 TROPION-Breast01 is a global, randomized, multicenter, open-label phase 3 trial evaluating the efficacy and safety of intravenous datopotamab deruxtecan (6 mg/kg) once per 21-day cycle versus investigator’s choice of single-agent chemotherapy (eribulin, capecitabine, vinorelbine or gemcitabine) in adult patients with unresectable or metastatic HR positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have progressed on and are not suitable for endocrine therapy per investigator assessment and have received at least one prior line of chemotherapy for unresectable or metastatic disease. Following disease progression or discontinuation of datopotamab deruxtecan or chemotherapy, patients had the option to receive a subsequent treatment at the discretion of their physician. Crossover between trial arms was not permitted. The dual primary endpoints of TROPION-Breast01 are PFS as assessed by BICR and OS. Key secondary endpoints include objective response rate, duration of response, investigator-assessed PFS, disease control rate, time to first subsequent therapy and safety. The PFS data and additional results for key secondary endpoints of TROPION-Breast01 were published in the Journal of Clinical Oncology . TROPION-Breast01 enrolled 732 patients in Africa, Asia, Europe, North America and South America. For more information visit ClinicalTrials.gov . About Hormone Receptor Positive, HER2 Negative Breast Cancer Breast cancer is the second most common cancer and one of the leading causes of cancer-related deaths worldwide. 1 More than 500,000 breast cancer cases were diagnosed in Europe in 2022. 2 While survival rates are high for those diagnosed with early breast cancer, only about 30% of patients diagnosed with or who progress to metastatic disease are expected to live five years following diagnosis. 3 Approximately 70% of diagnosed cases are considered what has been historically called HR positive, HER2 negative breast cancer (measured as HER2 score of IHC 0, IHC 1+ or IHC 2+/ISH-). 3 Endocrine therapies are widely given consecutively in the early lines of treatment for metastatic HR positive breast cancer. 4 However, after initial treatment, further efficacy from endocrine therapy is often limited. 4 The current standard of care following endocrine therapy is chemotherapy, which is associated with poor response rates and outcomes. 4,5,6,7 About Datopotamab Deruxtecan (Dato-DXd) Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2 directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC Technology, datopotamab deruxtecan is one of six DXd ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programs in AstraZeneca’s ADC scientific platform. Datopotamab deruxtecan is comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. Datopotamab deruxtecan is approved in Japan and the U.S. under the brand name DATROWAY for the treatment of adult patients with HR positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) unresectable or recurrent breast cancer after prior chemotherapy based on the results of the TROPION-Breast01 trial. About the Datopotamab Deruxtecan Clinical Development Program A comprehensive global clinical development program is underway with more than 20 trials evaluating the efficacy and safety of datopotamab deruxtecan across multiple cancers, including non-small cell lung cancer, triple negative breast cancer and HR positive, HER2 negative breast cancer. The program includes eight phase 3 trials in lung cancer and five phase 3 trials in breast cancer evaluating datopotamab deruxtecan as a monotherapy and in combination with other anticancer treatments in various settings. About the Daiichi Sankyo and AstraZeneca Collaboration Daiichi Sankyo and AstraZeneca entered into a global collaboration to jointly develop and commercialize ENHERTU ® in March 2019 and datopotamab deruxtecan in July 2020 , except in Japan where Daiichi Sankyo maintains exclusive rights for each ADC. Daiichi Sankyo is responsible for the manufacturing and supply of ENHERTU and datopotamab deruxtecan. About the ADC Portfolio of Daiichi Sankyo The Daiichi Sankyo ADC portfolio consists of seven ADCs in clinical development crafted from two distinct ADC technology platforms discovered in-house by Daiichi Sankyo. The ADC platform furthest in clinical development is Daiichi Sankyo’s DXd ADC Technology where each ADC consists of a monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. The DXd ADC portfolio currently consists of ENHERTU, a HER2 directed ADC, and datopotamab deruxtecan, a TROP2 directed ADC, which are being jointly developed and commercialized globally with AstraZeneca. Patritumab deruxtecan (HER3-DXd), a HER3 directed ADC, ifinatamab deruxtecan (I-DXd), a B7-H3 directed ADC, and raludotatug deruxtecan (R-DXd), a CDH6 directed ADC, are being jointly developed and commercialized globally with Merck & Co., Inc, Rahway, NJ, USA. DS-3939, a TA-MUC1 directed ADC, is being developed by Daiichi Sankyo. The second Daiichi Sankyo ADC platform consists of a monoclonal antibody attached to a modified pyrrolobenzodiazepine (PBD) payload. DS-9606, a CLDN6 directed PBD ADC, is the first of several planned ADCs in clinical development utilizing this platform. Ifinatamab deruxtecan, patritumab deruxtecan, raludotatug deruxtecan, DS-3939 and DS-9606 are investigational medicines that have not been approved for any indication in any country. Safety and efficacy have not been established. About Daiichi Sankyo Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.com . References _______________________________ 1 Bray F, et al. CA Cancer J Clin . 2024; 10.3322/caac.21834. 2 Globocan 2022. Europe . Accessed January 2025. 3 National Cancer Institute. SEER Cancer Stat Facts: Female Breast Cancer Subtypes . Accessed January 2025. 4 Manohar P, et al. Cancer Biol Med . 2022 Feb 15; 19(2):202–212. 5 Cortes J, et al. Lancet . 2011;377:914-923. 6 Yuan P, et al. Eur J Cancer . 2019;112:57-65. 7 Jerusalem G, et al. JAMA Oncol . 2018;4(10):1367–1374.

Phase 3Drug ApprovalADCClinical ResultLicense out/in

100 Deals associated with Eribulin mesylate

External Link

KEGG	Wiki	ATC	Drug Bank
D08914	Eribulin mesylate	L01XX41	DB08871

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Sarcoma	Japan	Eisai Co., Ltd.	29 Feb 2016
Soft Tissue Neoplasms	Japan	Eisai Co., Ltd.	29 Feb 2016
Breast Cancer	Japan	Eisai Co., Ltd.	22 Apr 2011
Liposarcoma	European Union	Eisai GmbH	17 Mar 2011
Liposarcoma	Iceland	Eisai GmbH	17 Mar 2011
Liposarcoma	Liechtenstein	Eisai GmbH	17 Mar 2011
Liposarcoma	Norway	Eisai GmbH	17 Mar 2011
Locally advanced breast cancer	European Union	Eisai GmbH	17 Mar 2011
Locally advanced breast cancer	Iceland	Eisai GmbH	17 Mar 2011
Locally advanced breast cancer	Liechtenstein	Eisai GmbH	17 Mar 2011
Locally advanced breast cancer	Norway	Eisai GmbH	17 Mar 2011
Metastatic breast cancer	United States	Eisai, Inc.	15 Nov 2010

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HER2 Positive Breast Cancer	Phase 3	Japan	Eisai Co., Ltd.	28 Aug 2017
HER2-negative breast cancer	Phase 3	China	Eisai Co., Ltd.	26 Sep 2013
Triple Negative Breast Cancer	Phase 3	China	Eisai Co., Ltd.	26 Sep 2013
Advanced Lung Non-Small Cell Carcinoma	Phase 3	United States	Eisai, Inc.	09 Dec 2011
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Japan	Eisai, Inc.	09 Dec 2011
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Australia	Eisai, Inc.	09 Dec 2011
Advanced Lung Non-Small Cell Carcinoma	Phase 3	France	Eisai, Inc.	09 Dec 2011
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Germany	Eisai, Inc.	09 Dec 2011
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Hong Kong	Eisai, Inc.	09 Dec 2011
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Italy	Eisai, Inc.	09 Dec 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


TriNetX platform (ESMO_SRC2025)	Not Applicable	Advanced Liposarcoma	1,828	Eribulin	zoxjrpsyos(kvnkesspct) = kclarpjzpu xcsknmmike (mgdybepmhj )	Positive	20 Mar 2025
				Trabectedin	zoxjrpsyos(kvnkesspct) = mwvxkyfftg xcsknmmike (mgdybepmhj )
NCT03222856 (KELLY study \| KELLY, CTgov)	Phase 2	Metastatic HER2-Negative Breast Carcinoma \| Hormone receptor positive HER2 negative breast cancer	44	Eribulin+pembrolizumab	ifmxwasant = aksbwddmjc hruisxzpcf (rxykouiltm, ukwmqmrces - gctvoezdno) View more	-	19 Feb 2025
NCT02338037 (Pubmed \| Cancer Chemother Pharmacol)	Early Phase 1	Brain Cancer	7	Eribulin 1.4 mg/m2	pfgaucrnuv(rglfstdtns) = xwbenpabfv eyjsssfnkq (nmmoojnqwq, 0.59)	Negative	01 Dec 2024
NCT03526679 (LEADER, CTgov)	Phase 1/2	Leiomyosarcoma \| Advanced Liposarcoma \| Soft Tissue Sarcoma ... View more	30	Eribulin+Lenvatinib	atdekotnhc = arubozcxju wwarmtoowj (foadkirweo, wmidmzdjxm - rgulfyyhca) View more	-	25 Nov 2024
NCT03331250 (CTgov)	Phase 2	Hemangiosarcoma \| Epithelioid Hemangioendothelioma	13	Eribulin	teorvflpwk = pdqaajrilf eysgtbybmu (hpjlgmzlve, ktojmodukw - esqtslposz) View more	-	08 Nov 2024
NCT03264547 (JBCRG-M06/EMERALD, ESMO2024) Manual	Phase 3	HER2 Positive Breast Cancer First line HER2 Positive	437	Eribulin (E) + Trastuzumab (H) + Pertuzumab (P)	bpkqtklfqv(qofamwbzaw) = vbjsfhawcf iqneftylmn (pgucpuxgku ) View more	Positive	16 Sep 2024
				Taxane (T) + Trastuzumab (H) + Pertuzumab (P)	bpkqtklfqv(qofamwbzaw) = mbroamzgqf iqneftylmn (pgucpuxgku ) View more
NCT03237780 (ESMO2024) Manual	Phase 2	Transitional Cell Carcinoma	33	Eribulin 1.4mg/m2 + Atezolizumab 1200mg/m2	sojifjujmk(vwhmwfwqfn) = wasesjbjio vunauihbyk (zyybtlftqp )	Positive	15 Sep 2024
				Atezolizumab 1200mg/m2	sojifjujmk(vwhmwfwqfn) = lmjxdrsyii vunauihbyk (zyybtlftqp )
NCT04061863 (KORNELIA trial, Pubmed \| Cancer Immunol Immunother)	Phase 2	Metastatic HER2-Negative Breast Carcinoma TMB \| HRD \| TP53 mutations ... View more	76	Eribulin and nivolumab combination	pbxyeffstk(ssomvfvkpe) = a potentially negative impact on efficacy kaxcahcszs (cykvjnxdnn ) View more	Positive	06 Aug 2024
NCT02640508 (ASCO2024) Manual	Phase 2	Advanced Malignant Solid Neoplasm Last line	29	Lenvatinib Eribulinulin combination therapy	hzdhyfnatg(kuuyprugyw) = rjwddybvoh gkhcxfycmf (zcsxjvtpiq ) View more	Positive	24 May 2024
				Lenvatinib+Eribulin (Vimentin-negative patients after adjusting for age, CD31, and CA9)	-
NCT05263882 (ASCO2024) Manual	Phase 2	HER2-negative breast cancer Last line \| Second line \| Third line HER2 Negative	70	Eribulin plus gemcitabine	dlbaunoldf(wwkhsqsppl) = fqncxboszk bmwrdyyzwj (arzjdypbiw ) View more	Positive	24 May 2024
				Eribulin plus gemcitabine (HR+HER2-)	dlbaunoldf(wwkhsqsppl) = jwkizuywlg bmwrdyyzwj (arzjdypbiw ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis